Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure
Open Access
- 9 March 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 35 (26) , 1760-1768
Abstract
The aim of this study was to determine whether angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-II receptor blocker (ARB) use is associated with lower rates of cardiovascular events in patients with stable coronary artery disease (CAD) but without heart failure (HF) receiving contemporary medical management. Using data from the Reduction of Atherothrombosis for Continued Health (REACH) registry, we examined, using propensity score approaches, relationships between cardiovascular outcomes and ACEI/ARB use (64.1% users) in 20 909 outpatients with stable CAD and free of HF at baseline. As internal control, we assessed the relation between statin use and outcomes. At 4-year follow-up, the risk of cardiovascular death, MI, or stroke (primary outcome) was similar in ACEI/ARB users compared with non-users (hazard ratio, 1.03; 95% confidence interval [CI], 0.91–1.16; P = 0.66). Similarly, the risk of the primary outcome and cardiovascular hospitalization for atherothrombotic events (secondary outcome) was not reduced in ACEI/ARB users (hazard ratio, 1.08; 95% CI, 1.01–1.16; P = 0.04), nor were the rates of any of its components. Analyses using propensity score matching yielded similar results, as did sensitivity analyses accounting for missing covariates, changes in medications over time, or analysing separately ACEI and ARB use. In contrast, in the same cohort, statin use was associated with lower rates for all outcomes. Use of ACEI/ARB was not associated with better outcomes in stable CAD outpatients without HF. The benefit of ACEI/ARB seen in randomized clinical trials was not replicated in this large contemporary cohort, which questions their value in this specific subset.Keywords
Funding Information
- NIH
This publication has 39 references indexed in Scilit:
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDEuropean Heart Journal, 2013
- 2013 ESH/ESC Guidelines for the management of arterial hypertensionEuropean Heart Journal, 2013
- 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive SummaryCirculation, 2012
- ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial InfarctionCirculation, 2007
- Angiotensin-converting enzyme inhibitors: ischemia is not the correct measure of benefit**Editorials published in the Journal of the American College of Cardiologyreflect the views of the author and do not necessarily represent the views of JACCor the American College of Cardiology.JACC, 2003
- Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or BothNew England Journal of Medicine, 2003
- Comparison of 2 Methods for Calculating Adjusted Survival Curves From Proportional Hazards ModelsJAMA, 2001
- Validating recommendations for coronary angiography following acute myocardial infarction in the elderlyJournal of Clinical Epidemiology, 2001
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control groupStatistics in Medicine, 1998